ARID4A and CCNA2

Number of citations of the paper that reports this interaction (PubMedID 21148318)
61

Data Source:
BioGRID (enzymatic study)

		ARID4A	CCNA2
Description		AT-rich interaction domain 4A	cyclin A2
Image
GO Annotations	Cellular Component	Nucleus Nucleoplasm Plasma Membrane Transcription Repressor Complex Sin3-type Complex	Cyclin-dependent Protein Kinase Holoenzyme Complex Female Pronucleus Male Pronucleus Nucleus Nucleoplasm Cytoplasm Microtubule Organizing Center Cytosol Cyclin A2-CDK1 Complex Cyclin A2-CDK2 Complex
	Molecular Function	Transcription Cis-regulatory Region Binding DNA Binding Double-stranded DNA Binding	Protein Binding Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Protein Kinase Binding Protein Domain Specific Binding
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Chromatin Organization Regulation Of DNA-templated Transcription Regulation Of Transcription By RNA Polymerase II Transcription By RNA Polymerase II Spermatogenesis Cell Differentiation Negative Regulation Of Cell Migration Negative Regulation Of Transforming Growth Factor Beta Receptor Signaling Pathway Negative Regulation Of DNA-templated Transcription Positive Regulation Of Transcription By RNA Polymerase II Erythrocyte Development Genomic Imprinting Establishment Of Sertoli Cell Barrier Negative Regulation Of Stem Cell Population Maintenance Positive Regulation Of Stem Cell Population Maintenance	G1/S Transition Of Mitotic Cell Cycle G2/M Transition Of Mitotic Cell Cycle Regulation Of DNA Replication DNA-templated Transcription Ras Protein Signal Transduction Animal Organ Regeneration Response To Estradiol Response To Glucagon Cellular Response To Platelet-derived Growth Factor Stimulus Post-translational Protein Modification Cellular Response To Leptin Stimulus Mitotic Cell Cycle Phase Transition Cell Cycle G1/S Phase Transition Positive Regulation Of DNA-templated Transcription Positive Regulation Of Fibroblast Proliferation Cell Division Cellular Response To Cocaine Cellular Response To Luteinizing Hormone Stimulus Cellular Response To Estradiol Stimulus Cellular Response To Hypoxia Cellular Response To Nitric Oxide Cochlea Development Cellular Response To Insulin-like Growth Factor Stimulus Positive Regulation Of DNA Biosynthetic Process
Pathways		HDACs deacetylate histones Potential therapeutics for SARS	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 Telomere Extension By Telomerase Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Ub-specific processing proteases Processing of DNA double-strand break ends TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation G2 Phase Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition G2/M DNA replication checkpoint p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
Drugs			4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine 6-O-Cyclohexylmethyl Guanine [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE Variolin B
Diseases
GWAS		Age at first sexual intercourse ( 34211149) Alcohol consumption (drinks per week) ( 30679032) Alcohol consumption in current drinkers ( 28937693) Brain morphology (MOSTest) ( 32665545) Coronary artery disease ( 29212778 33020668) Mean corpuscular volume ( 32888494) Mean platelet volume ( 32888494) Mean spheric corpuscular volume ( 32888494) Problematic alcohol use ( 32451486) Venous thromboembolism ( 31420334) Waist-to-hip ratio adjusted for BMI (additive genetic model) ( 30778226)	Mean corpuscular hemoglobin ( 32888494)
Interacting Genes		15 interacting genes: BRMS1 CCNA2 CCNB1 CCND1 CCNE1 CDK1 CDK2 CDK4 EID1 H3C14 H4C16 HDAC1 HDAC2 HDAC3 SIN3A	46 interacting genes: ARID4A BRCA1 BRCA2 BTG1 BUB1B CALM1 CDC20 CDC25C CDC6 CDK1 CDK2 CDK3 CDKN1A CDKN1B CDT1 DTNBP1 E2F1 E2F3 FANCC FEN1 H1-1 H1-5 HERC5 HIRA ITGB3BP KAT2B MAD2L1 MAGEA11 MYBL2 NFYA PGR PRC1 PSMD4 PTMA RAD23A RB1 RBL1 RBL2 SKP1 SKP2 SP1 TAF1 TP53 TRAF3IP1 UBTF USP37
Entrez ID		5926	890
HPRD ID		01575	00453
Ensembl ID		ENSG00000032219	ENSG00000145386
Uniprot IDs		P29374 Q05CG0	P20248
PDB IDs		2LCC 2MAM 2YRV 6BPH 6L87 7SMC 7V8N	1E9H 1FIN 1FVV 1GY3 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1JST 1JSU 1OGU 1OI9 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P5E 1PKD 1QMZ 1URC 1VYW 2BKZ 2BPM 2C4G 2C5N 2C5O 2C5V 2C5X 2C6T 2CCH 2CCI 2CJM 2I40 2IW6 2IW8 2IW9 2UUE 2UZB 2UZD 2UZE 2UZL 2V22 2WEV 2WFY 2WHB 2WIH 2WIP 2WMA 2WMB 2WPA 2WXV 2X1N 3EID 3EJ1 3EOC 3F5X 4BCK 4BCM 4BCN 4BCP 4CFM 4CFN 4CFU 4CFV 4CFW 4CFX 4EOI 4EOJ 4EOK 4EOL 4EOM 4EON 4EOO 4EOP 4EOQ 4EOR 4EOS 4FX3 5CYI 5IF1 5LMK 5NEV 6ATH 6GVA 6P3W 6Q6G 6Q6H 6RIJ 6SG4 7ACK 7B5L 7B5R 7B7S 7LUO 7MKX 7QHL 8B54 8BYA 8BZO
Enriched GO Terms of Interacting Partners?		Cell Cycle G1/S Phase Transition G1/S Transition Of Mitotic Cell Cycle Cyclin-dependent Protein Kinase Holoenzyme Complex Mitotic Cell Cycle Phase Transition Positive Regulation Of G2/M Transition Of Mitotic Cell Cycle Cell Cycle Phase Transition Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Positive Regulation Of Cell Cycle G2/M Phase Transition Positive Regulation Of Mitotic Cell Cycle Phase Transition Nucleoplasm Regulation Of G2/M Transition Of Mitotic Cell Cycle Positive Regulation Of Cell Cycle Phase Transition Regulation Of Cell Cycle G2/M Phase Transition Protein Lysine Delactylase Activity Negative Regulation Of Transcription By RNA Polymerase II Positive Regulation Of Mitotic Cell Cycle Regulation Of RNA Metabolic Process Protein Decrotonylase Activity Histone Decrotonylase Activity Regulation Of Mitotic Cell Cycle Sin3-type Complex Negative Regulation Of Stem Cell Population Maintenance Regulation Of Nucleobase-containing Compound Metabolic Process Negative Regulation Of Macromolecule Biosynthetic Process Regulation Of Mitotic Cell Cycle Phase Transition Negative Regulation Of Biosynthetic Process Positive Regulation Of Cell Population Proliferation Negative Regulation Of DNA-templated Transcription Negative Regulation Of RNA Biosynthetic Process NF-kappaB Binding Cyclin Binding Regulation Of DNA-templated Transcription Regulation Of RNA Biosynthetic Process Regulation Of Transcription By RNA Polymerase II Chromatin Remodeling Negative Regulation Of RNA Metabolic Process Negative Regulation Of Macromolecule Metabolic Process Regulation Of Cell Cycle Phase Transition Histone Deacetylase Complex Cell Division Positive Regulation Of Cell Cycle Process Negative Regulation Of Nucleobase-containing Compound Metabolic Process Histone Deacetylase Activity, Hydrolytic Mechanism Histone Deacetylase Binding Positive Regulation Of Stem Cell Population Maintenance Negative Regulation Of Metabolic Process G2/M Transition Of Mitotic Cell Cycle Regulation Of Gene Expression Chromatin Organization Cell Cycle G2/M Phase Transition	Nucleoplasm Regulation Of Cell Cycle Process Regulation Of Cell Cycle Regulation Of Cell Cycle Phase Transition Mitotic Cell Cycle Phase Transition Regulation Of Mitotic Cell Cycle Phase Transition Cell Cycle Phase Transition Negative Regulation Of Cell Cycle Process Negative Regulation Of Cell Cycle Negative Regulation Of Cell Cycle Phase Transition Regulation Of Mitotic Cell Cycle Nucleus Negative Regulation Of Mitotic Cell Cycle Negative Regulation Of Mitotic Cell Cycle Phase Transition Regulation Of Macromolecule Metabolic Process Regulation Of Primary Metabolic Process G1/S Transition Of Mitotic Cell Cycle Cell Cycle G1/S Phase Transition Regulation Of Metabolic Process Regulation Of Nucleobase-containing Compound Metabolic Process Chromatin Organization Regulation Of Cell Cycle G1/S Phase Transition Cell Division Regulation Of DNA Metabolic Process Regulation Of G1/S Transition Of Mitotic Cell Cycle Regulation Of Chromosome Organization Regulation Of DNA Replication Positive Regulation Of Cell Cycle Regulation Of Cell Cycle G2/M Phase Transition Chromatin Remodeling Chromosome Organization Positive Regulation Of Nucleobase-containing Compound Metabolic Process G2/M Transition Of Mitotic Cell Cycle Signal Transduction In Response To DNA Damage Cell Cycle G2/M Phase Transition Regulation Of DNA-templated Transcription Regulation Of RNA Biosynthetic Process Regulation Of G2/M Transition Of Mitotic Cell Cycle Regulation Of Sister Chromatid Segregation Negative Regulation Of G1/S Transition Of Mitotic Cell Cycle Regulation Of Cell Population Proliferation Cyclin Binding Positive Regulation Of Cell Cycle Process Regulation Of Phosphorus Metabolic Process Negative Regulation Of Cell Cycle G1/S Phase Transition Mitotic DNA Integrity Checkpoint Signaling Positive Regulation Of Macromolecule Metabolic Process Regulation Of Chromosome Segregation Mitotic Checkpoint Complex Regulation Of Lipid Kinase Activity
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?